

SAMPLE CODING

Wet-Age Related Macular Degeneration (wet AMD)

TYPE	CODE	DESCRIPTION
Diagnosis: ICD-10-CM	H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
	H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
	H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
	H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
	H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
	H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
	H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
	H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
	H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
	H35.3290	Exudative age-related macular degeneration, unspecified eye, stage unspecified
	H35.3291	Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization
	H35.3292	Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization
	Drug: HCPCS	J2778
HCPCS: Modifier* Note: Beginning July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded.	JZ	Zero drug amount discarded/not administered to any patient

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

*The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit [CMS.gov](https://www.cms.gov).

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

for **LUCENTIS**[®]
(ranibizumab injection)

Wet-Age Related Macular Degeneration (wet AMD) (cont)

TYPE	CODE		DESCRIPTION
Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	10-digit	11-digit	
	50242-080-03	50242-0080-03	LUCENTIS 0.5-mg prefilled syringe
Administration procedures: CPT	67028		Intravitreal injection of a pharmacologic agent (separate procedure)
	CPT modifier	–LT	Left eye modifier
		–RT	Right eye modifier

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

LUCENTIS[®] is a registered trademark of Genentech, Inc.

For important safety information, please see LUCENTIS full [prescribing information](#).